Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year High - Here's What Happened

Key Points

• Aurinia Pharmaceuticals (NASDAQ:AUPH) reached a new **52-week high** of $12.87, closing at $12.71 with a trading volume of 145,754 shares.
• Analysts have set a new **average price target of $12.00** for Aurinia, with HC Wainwright maintaining a **$17.00** price objective and Royal Bank of Canada raising theirs from $8.00 to **$9.00**.
• Insider trading activity includes Director Kevin Tang acquiring **200,000 shares** at $11.68 per share, increasing his ownership stake in the company.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP reached a new 52-week high during trading on Friday . The stock traded as high as $12.87 and last traded at $12.71, with a volume of 145754 shares changing hands. The stock had previously closed at $12.78.

Analyst Upgrades and Downgrades

Several analysts recently commented on AUPH shares. HC Wainwright restated a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Royal Bank Of Canada raised their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $13.00.

Aurinia Pharmaceuticals Stock Down 1.7%

The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 28.71 and a beta of 1.26. The business's fifty day moving average is $10.96 and its two-hundred day moving average is $9.05.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Insider Transactions at Aurinia Pharmaceuticals

In other news, Director Kevin Tang purchased 1,000,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was bought at an average price of $10.12 per share, for a total transaction of $10,120,000.00. Following the completion of the purchase, the director directly owned 11,029,500 shares of the company's stock, valued at $111,618,540. The trade was a 9.97% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased a total of 1,300,000 shares of company stock valued at $13,590,000 in the last ninety days. 12.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at about $27,000. GAMMA Investing LLC increased its position in Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,744 shares in the last quarter. MAI Capital Management acquired a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $39,000. USA Financial Formulas acquired a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $50,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $60,000. 36.83% of the stock is owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.